Cargando…

BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models

Several cancer cell types, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL) upregulate antiapoptotic Bcl-2 to cope with oncogenic stress. BH3 mimetics targeting Bcl-2’s hydrophobic cleft have been developed, including venetoclax as a promising anticancer precisi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vervloessem, Tamara, Sasi, Binu K., Xerxa, Elena, Karamanou, Spyridoula, Kale, Justin, La Rovere, Rita M., Chakraborty, Supriya, Sneyers, Flore, Vogler, Meike, Economou, Anastassios, Laurenti, Luca, Andrews, David W., Efremov, Dimitar G., Bultynck, Geert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498462/ https://www.ncbi.nlm.nih.gov/pubmed/32943617 http://dx.doi.org/10.1038/s41419-020-02944-6

Ejemplares similares

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth
por: Deng, Jiusheng, et al.
Publicado: (2016)

Antagonizing Bcl-2′s BH4 domain in cancer
por: Vervloessem, Tamara, et al.
Publicado: (2015)

Allosteric cross-talk between the hydrophobic cleft and the BH4 domain of Bcl-2 in control of inositol 1,4,5-trisphosphate receptor activity
por: Shapovalov, George, et al.
Publicado: (2022)

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
por: Kerkhofs, Martijn, et al.
Publicado: (2020)

A direct comparison of selective BH3-mimetics reveals BCL-X(L), BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
por: Bierbrauer, Annika, et al.
Publicado: (2020)

BH4 domain peptides derived from Bcl-2/Bcl-XL as novel tools against acute pancreatitis
por: Vervliet, Tim, et al.
Publicado: (2018)

Bcl-xL acts as an inhibitor of IP(3)R channels, thereby antagonizing Ca(2+)-driven apoptosis
por: Rosa, Nicolas, et al.
Publicado: (2021)

ABT‐199 (Venetoclax), a BH3‐mimetic Bcl‐2 inhibitor, does not cause Ca(2+)‐signalling dysregulation or toxicity in pancreatic acinar cells
por: Jakubowska, Monika A, et al.
Publicado: (2018)

Selective regulation of IP(3)-receptor-mediated Ca(2+) signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl
por: Monaco, G, et al.
Publicado: (2012)

Mutual Regulation of Bcl-2 Proteins Independent of the BH3 Domain as Shown by the BH3-Lacking Protein Bcl-x(AK)
por: Plötz, Michael, et al.
Publicado: (2012)

Targeting BCL2-Proteins for the Treatment of Solid Tumours
por: Vogler, Meike
Publicado: (2014)

BCL2DB: database of BCL-2 family members and BH3-only proteins
por: Rech de Laval, Valentine, et al.
Publicado: (2014)

Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax
por: Vervloessem, Tamara, et al.
Publicado: (2017)

Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma
por: Smith, Victoria M., et al.
Publicado: (2020)

Ryanodine receptors are targeted by anti-apoptotic Bcl-X(L) involving its BH4 domain and Lys87 from its BH3 domain
por: Vervliet, Tim, et al.
Publicado: (2015)

Keeping an eye on Ca(2+) signalling to tackle dry eye diseases
por: Sneyers, Flore, et al.
Publicado: (2021)

The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist
por: Rautureau, G J P, et al.
Publicado: (2012)

Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer
por: Kanakaveti, Vishnupriya, et al.
Publicado: (2022)

A Reporter System for Fast Quantitative Monitoring of Type 3 Protein Secretion in Enteropathogenic E. coli
por: Barkalita, Luit, et al.
Publicado: (2020)

Alpha-Helical Destabilization of the Bcl-2-BH4-Domain Peptide Abolishes Its Ability to Inhibit the IP(3) Receptor
por: Monaco, Giovanni, et al.
Publicado: (2013)

Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2
por: Liu, Qian, et al.
Publicado: (2019)

Regulation of the Autophagic Bcl-2/Beclin 1 Interaction
por: Decuypere, Jean-Paul, et al.
Publicado: (2012)

Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
por: Oakes, SR, et al.
Publicado: (2012)

BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
por: Ramesh, Prashanthi, et al.
Publicado: (2020)

The BDA; together
por: Woodrow, Martin
Publicado: (2020)

BDA AGMs
Publicado: (2023)

A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2
por: Lavik, Andrew R., et al.
Publicado: (2015)

A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma
por: Arulananda, Surein, et al.
Publicado: (2021)

BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics
por: Touzeau, Cyrille, et al.
Publicado: (2015)

Constitutive IP(3) signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP(3) receptor disruptor BIRD-2
por: Bittremieux, Mart, et al.
Publicado: (2018)

Molecular Interactions of Prodiginines with the BH3 Domain of Anti-Apoptotic Bcl-2 Family Members
por: Hosseini, Ali, et al.
Publicado: (2013)

The BH3 only Bcl-2 family member BNIP3 regulates cellular proliferation
por: Singh, Amandeep, et al.
Publicado: (2018)

BH4-mimetics and -antagonists: an emerging class of Bcl-2 protein modulators for cancer therapy
por: Nougarède, Adrien, et al.
Publicado: (2018)

Bcl-2 regulates pyroptosis and necroptosis by targeting BH3-like domains in GSDMD and MLKL
por: Shi, Chong-Shan, et al.
Publicado: (2019)

Competition Between Phenothiazines and BH3 Peptide for the Binding Site of the Antiapoptotic BCL-2 Protein
por: do Carmo, Aline Lagoeiro, et al.
Publicado: (2020)

Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak
por: Uren, Rachel T., et al.
Publicado: (2007)

Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme
por: Cartron, P F, et al.
Publicado: (2012)

Domain-specific insight into the recognition of BH3-death motifs by the pro-survival Bcl-2 protein
por: Mushtaq, Ameeq Ul, et al.
Publicado: (2022)

Structural Investigation of Orf Virus Bcl-2 Homolog ORFV125 Interactions with BH3-Motifs from BH3-Only Proteins Puma and Hrk
por: Suraweera, Chathura D., et al.
Publicado: (2021)

Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions
por: Finnegan, N M, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_14majl3tilftepp5ipibhmogl0